Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen and Genentech to Study Genetics of Cancer

NEW YORK, Dec. 6 (GenomeWeb News) - Perlegen Sciences announced today that it has begun a collaboration with Genentech to study the genetics of cancer.

 

The companies hope to apply findings to the discovery and development of targeted medicines and molecular diagnostics for cancer.

 

Perlegen uses Affymetrix's GeneChip technology in its high-throughput oligonucleotide array approach.

 

Terms of the agreement were not disclosed.

The Scan

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.